miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity

EMBO Molecular Medicine

Volumn 4, Issue 9, 2012, Pages 882-895

  Allen, Ryan M ^a   Marquart, Tyler J ^a   Albert, Carolyn J ^a   Suchy, Frederick J ^b   Wang, David Q H ^a   Ananthanarayanan, Meenakshisundaram ^c   Ford, David A ^a,d   Baldán, Ángel ^a,d  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAINT LOUIS UNIVERSITY   (United States)

Author keywords

ABCB11; ATP8B1; Cholestasis; MiR 33; Statins

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEMBRANE PROTEIN; MICRORNA; MICRORNA 33; PROTEIN ABCB11; PROTEIN ATP8B1; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE SECRETION; CHOLELITHIASIS; CHOLESTASIS; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DIETARY INTAKE; GALLBLADDER; GENE SILENCING; IN VIVO STUDY; INTRON; ISOTOPE LABELING; LETHALITY; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RNA ANALYSIS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BILE; CELLS, CULTURED; DIET; GENE EXPRESSION REGULATION; HEPATOCYTES; LIVER; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; MODELS, BIOLOGICAL; SIMVASTATIN;

EID: 84865794377     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.1002/emmm.201201228     Document Type: Article

References (66)

1. Abu Rajab M, Kaplan MM (2010) Statins in primary biliary cirrhosis: are they safe? Dig Dis Sci 55: 2086-2088.
2. Alvarez L, Jara P, Sanchez-Sabate E, Hierro L, Larrauri J, Diaz MC, Camarena C, De La Vega A, Frauca E, Lopez-Collazo E et al (2004) Reduced hepatic expression of Farnesoid X Receptor in hereditary cholestasis associated to mutation in ATP8B1. Hum Mol Genet 13: 2451-2460.
3. Annema W, Dikkers A, Freark de Boer J, Gautier T, Rensen PC, Rader DJ, Tietge UJ (2012) ApoE promotes hepatic selective uptake but not RCT due to increased ABCA1-mediated cholesterol efflux to plasma. J Lipid Res 53: 929-940.
4. Batey RG, Harvey M (2002) Cholestasis associated with the use of pravastatin sodium. Med J Aust 176: 561.
5. Bennett MK, Seo YK, Datta S, Shin DJ, Osborne TF (2008) Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver. J Biol Chem 283: 15628-15637.
6. Bligh EG, Dyer WJ (1959) A rapid method of total lipid extraction and purification. Can J Med Sci 37: 911-917.
7. Cai SY, Gautam S, Nguyen T, Soroka CJ, Rahner C, Boyer JL (2009) ATP8B1 deficiency disrupts the bile canalicular membrane bilayer structure in hepatocytes, but FXR expression and activity are maintained. Gastroenterology 136: 1060-1069.
8. Chen F, Ananthanarayanan M, Emre S, Neimark E, Bull LN, Knisely AS, Strautnieks SS, Thompson RJ, Magid MS, Gordon R, et al (2004) Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity. Gastroenterology 126: 756-764.
9. Chen F, Ellis E, Strom SC, Shneider BL (2010) ATPase Class I Type 8B Member 1 and protein kinase C zeta induce the expression of the canalicular bile salt export pump in human hepatocytes. Pediatr Res 67: 183-187.
10. Davalos A, Goedeke L, Smibert P, Ramirez CM, Warrier NP, Andreo U, Cirera-Salinas D, Rayner K, Suresh U, Pastor-Pareja JC, et al (2011) miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci USA 108: 9232-9237.
11. Davit-Spraul A, Fabre M, Branchereau S, Baussan C, Gonzales E, Stieger B, Bernard O, Jacquemin E (2010) ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology 51: 1645-1655.
12. de Castro ML, Hermo JA, Baz A, de Luaces C, Perez R, Clofent J (2006) Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterol Hepatol 29: 21-24.
13. Emerick KM, Whitington PF (2002) Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 35: 1501-1506.
14. Englert C, Grabhorn E, Burdelski M, Ganschow R (2006) Liver transplantation in children with Alagille syndrome: indications and outcome. Pediatr Transplant 10: 154-158.
15. Esteller A (2008) Physiology of bile secretion. World J Gastroenterol 14: 5641-5649.
16. Ford DA, Monda JK, Brush RS, Anderson RE, Richards MJ, Fliesler SJ (2008) Lipidomic analysis of the retina in a rat model of Smith-Lemli-Opitz syndrome: alterations in docosahexaenoic acid content of phospholipid molecular species. J Neurochem 105: 1032-1047.
17. Frankenberg T, Miloh T, Chen FY, Ananthanarayanan M, Sun AQ, Balasubramaniyan N, Arias I, Setchell KD, Suchy FJ, Shneider BL (2008) The membrane protein ATPase class I type 8B member 1 signals through protein kinase C zeta to activate the farnesoid X receptor. Hepatology 48: 1896-1905.
18. Gadaleta RM, van Mil SW, Oldenburg B, Siersema PD, Klomp LW, van Erpecum KJ (2010) Bile acids and their nuclear receptor FXR: relevance for hepatobiliary and gastrointestinal disease. Biochim Biophys Acta 1801: 683-692.
19. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, Leclercq IA, MacDougald OA, Bommer GT (2010) Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 285: 33652-33661.
20. Han X, Gross RW (2001) Quantitative analysis and molecular species fingerprinting of triacylglyceride molecular species directly from lipid extracts of biological samples by electrospray ionization tandem mass spectrometry. Anal Biochem 295: 88-100.
21. Han X, Gross RW (2005) Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. Mass Spectrom Rev 24: 367-412.
22. Harris MJ, Le Couteur DG, Arias IM (2005) Progressive familial intrahepatic cholestasis: genetic disorders of biliary transporters. J Gastroenterol Hepatol 20: 807-817.
23. Hori T, Nguyen JH, Uemoto S (2010) Progressive familial intrahepatic cholestasis. Hepatobiliary Pancreat Dis Int 9: 570-578.
24. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, Kinoshita M, Kuwabara Y, Marusawa H, Iwanaga Y, et al (2010) MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 107: 17321-17326.
25. Horton JD, Bashmakov Y, Shimomura I, Shimano H (1998) Regulation of sterol regulatory element binding proteins in livers of fasted and refed mice. Proc Natl Acad Sci USA 95: 5987-5992.
26. Hubacek JA, Berge KE, Cohen JC, Hobbs HH (2001) Mutations in ATP-cassette binding proteins G5 (ABCG5) and G8 (ABCG8) causing sitosterolemia. Hum Mutat 18: 359-360.
27. Khanuja B, Cheah YC, Hunt M, Nishina PM, Wang DQ, Chen HW, Billheimer JT, Carey MC, Paigen B (1995) Lith1, a major gene affecting cholesterol gallstone formation among inbred strains of mice. Proc Natl Acad Sci USA 92: 7729-7733.
28. Khera AV, Rader DJ (2010) Future therapeutic directions in reverse cholesterol transport. Curr Atheroscler Rep 12: 73-81.
29. Koh S, Takada T, Kukuu I, Suzuki H (2009) FIC1-mediated stimulation of FXR activity is decreased with PFIC1 mutations in HepG2 cells. J Gastroenterol 44: 592-600.
30. Kubitz R, Keitel V, Haussinger D (2005) Inborn errors of biliary canalicular transport systems. Methods Enzymol 400: 558-569.
31. Lammert F, Wang DQ, Hillebrandt S, Geier A, Fickert P, Trauner M, Matern S, Paigen B, Carey MC (2004) Spontaneous cholecysto- and hepatolithiasis in Mdr2-/- mice: a model for low phospholipid-associated cholelithiasis. Hepatology 39: 117-128.
32. Marquart TJ, Allen RM, Ory DS, Baldan A (2010) miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 107: 12228-12232.
33. Martinez-Fernandez P, Hierro L, Jara P, Alvarez L (2009) Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064. Am J Physiol Gastrointest Liver Physiol 296: G1119- G1129.
34. Merli M, Bragazzi MC, Giubilo F, Callea F, Attili AF, Alvaro D (2010) Atorvastatin-induced prolonged cholestasis with bile duct damage. Clin Drug Investig 30: 205-209.
35. Morotti RA, Suchy FJ, Magid MS (2011) Progressive familial intrahepatic cholestasis (PFIC) type 1, 2, and 3: a review of the liver pathology findings. Semin Liver Dis 31: 3-10.
36. Moschetta A, Bookout AL, Mangelsdorf DJ (2004) Prevention of cholesterol gallstone disease by FXR agonists in a mouse model. Nat Med 10: 1352-1358.
37. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM (2010) MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 238: 1566-1569.
38. Nijstad N, Wiersma H, Gautier T, van der Giet M, Maugeais C, Tietge UJ (2009) Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J Biol Chem 284: 6093-6100.
39. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ (2011) Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology 140: 1043-1051.
40. Paulusma CC, Groen A, Kunne C, Ho-Mok KS, Spijkerboer AL, Rudi de Waart D, Hoek FJ, Vreeling H, Hoeben KA, van Marle J, et al (2006) Atp8b1 deficiency in mice reduces resistance of the canalicular membrane to hydrophobic bile salts and impairs bile salt transport. Hepatology 44: 195-204.
41. Paulusma CC, Folmer DE, Ho-Mok KS, de Waart DR, Hilarius PM, Verhoeven AJ, Oude Elferink RP (2008) ATP8B1 requires an accessory protein for endoplasmic reticulum exit and plasma membrane lipid flippase activity. Hepatology 47: 268-278.
42. Pawlikowska L, Groen A, Eppens EF, Kunne C, Ottenhoff R, Looije N, Knisely AS, Killeen NP, Bull LN, Elferink RP, et al (2004) A mouse genetic model for familial cholestasis caused by ATP8B1 mutations reveals perturbed bile salt homeostasis but no impairment in bile secretion. Hum Mol Genet 13: 881-892.
43. Portincasa P, Palasciano G, Svelto M, Calamita G (2008) Aquaporins in the hepatobiliary tract. Which, where and what they do in health and disease. Eur J Clin Invest 38: 1-10.
44. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH (2009) The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 50 Suppl: S189-S194.
45. Rahier JF, Rahier J, Leclercq I, Geubel AP (2008) Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol Belg 71: 318-320.
46. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, Moore KJ, Fernandez-Hernando C (2010) miR-33 contributes to the regulation of cholesterol homeostasis. Science 238: 1570-1573.
47. Rayner KJ, Esau CC, Hussain FN, McDaniel AL, Marshall SM, van Gils JM, Ray TD, Sheedy FJ, Goedeke L, Liu X, et al (2011a) Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 478: 404-407.
48. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, et al (2011b) Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 121: 2921-2931.
49. Ridruejo E, Mando OG (2002) Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol 37: 165-166.
50. Shah S, Sanford UR, Vargas JC, Xu H, Groen A, Paulusma CC, Grenert JP, Pawlikowska L, Sen S, Elferink RP, et al (2010) Strain background modifies phenotypes in the ATP8B1-deficient mouse. PLoS One 5: e8984.
51. Stanca CM, Bach N, Allina J, Bodian C, Bodenheimer H, Jr., Odin JA (2008) Atorvastatin does not improve liver biochemistries or Mayo Risk Score in primary biliary cirrhosis. Dig Dis Sci 53: 1988-1993.
52. Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, Marz W, Trauner M (2007) Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776-784.
53. Stojakovic T, Claudel T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Sourij H, Stauber RE, Winkler K, Marz W, et al (2010) Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. Atherosclerosis 209: 178-183.
54. Temel RE, Sawyer JK, Yu L, Lord C, Degirolamo C, McDaniel A, Marshall S, Wang N, Shah R, Rudel LL, et al (2010) Biliary sterol secretion is not required for macrophage reverse cholesterol transport. Cell Metab 12: 96-102.
55. Tietge UJ, Nijstad N, Havinga R, Baller JF, van der Sluijs FH, Bloks VW, Gautier T, Kuipers F (2008) Secretory phospholipase A2 increases SR-BI-mediated selective uptake from HDL but not biliary cholesterol secretion. J Lipid Res 49: 563-571.
56. Torres M, Sobrino J, Asensio C, Lopez D (2002) Acute cholestatic hepatitis induced by cerivastatin. Med Clin 118: 717.
57. Ujhazy P, Ortiz D, Misra S, Li S, Moseley J, Jones H, Arias IM (2001) Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology 34: 768-775.
58. van der Woerd WL, van Mil SW, Stapelbroek JM, Klomp LW, van de Graaf SF, Houwen RH (2010) Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol 24: 541-553.
59. Wang X, Rader DJ (2007) Molecular regulation of macrophage reverse cholesterol transport. Curr Opin Cardiol 22: 368-372.
60. Wang R, Lam P, Liu L, Forrest D, Yousef IM, Mignault D, Phillips MJ, Ling V (2003) Severe cholestasis induced by cholic acid feeding in knockout mice of sister of P-glycoprotein. Hepatology 38: 1489-1499.
61. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ (2007) Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 117: 2216-2224.
62. Wiersma H, Gatti A, Nijstad N, Kuipers F, Tietge UJ (2009) Hepatic SR-BI, not endothelial lipase, expression determines biliary cholesterol secretion in mice. J Lipid Res 50: 1571-1580.
63. Yu L, Hammer RE, Li-Hawkins J, Von Bergmann K, Lutjohann D, Cohen JC, Hobbs HH (2002) Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion. Proc Natl Acad Sci USA 99: 16237-16242.
64. Yu L, Gupta S, Xu F, Liverman AD, Moschetta A, Mangelsdorf DJ, Repa JJ, Hobbs HH, Cohen JC (2005) Expression of ABCG5 and ABCG8 is required for regulation of biliary cholesterol secretion. J Biol Chem 280: 8742-8747.
65. Zadelaar S, Kleemann R, Verschuren L, de Vries-Van der Weij J, van der Hoorn J, Princen HM, Kooistra T (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27: 1706-1721.
66. Zhang Y, Edwards PA (2008) FXR signaling in metabolic disease. FEBS Lett 582: 10-18.